| Literature DB >> 31064849 |
Lisa Kaminski1, Stéphanie Torrino1, Maeva Dufies2, Zied Djabari3, Romain Haider1,4, François-René Roustan1,3, Emilie Jaune1, Kathiane Laurent1, Nicolas Nottet1, Jean-François Michiels5, Maeva Gesson1, Stéphane Rocchi1, Nathalie M Mazure1, Matthieu Durand4, Jean-François Tanti1, Damien Ambrosetti5, Stephan Clavel1, Issam Ben-Sahra3, Frédéric Bost6.
Abstract
Although tumorigenesis is dependent on the reprogramming of cellular metabolism, the metabolic pathways engaged in the formation of metastases remain largely unknown. The transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) plays a pleiotropic role in the control of cancer cell metabolism and has been associated with a good prognosis in prostate cancer. Here, we show that PGC1α represses the metastatic properties of prostate cancer cells via modulation of the polyamine biosynthesis pathway. Mechanistically, PGC1α inhibits the expression of c-MYC and ornithine decarboxylase 1 (ODC1), the rate-limiting enzyme for polyamine synthesis. Analysis of in vivo metastases and clinical data from patients with prostate cancer support the proposition that the PGC1α/c-MYC/ODC1 axis regulates polyamine biosynthesis and prostate cancer aggressiveness. In conclusion, downregulation of PGC1α renders prostate cancer cells dependent on polyamine to promote metastasis. SIGNIFICANCE: These findings show that a major regulator of mitochondrial metabolism controls polyamine synthesis and prostate cancer aggressiveness, with potential applications in therapy and identification of new biomarkers. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31064849 PMCID: PMC7293888 DOI: 10.1158/0008-5472.CAN-18-2043
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701